Today, the Chairman of Incyte Corp (NASDAQ: INCY), Herve Hoppenot, bought shares of INCY for $914.1K.
This recent transaction increases Herve Hoppenot’s holding in the company by 5.73% to a total of $16.89 million. In addition to Herve Hoppenot, 2 other INCY executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
The company has a one-year high of $140.11 and a one-year low of $60.23. Currently, Incyte Corp has an average volume of 2.67M. The Company has a book value per share of 7.9096.
24 different firms, including Argus Research and Barclays, currently also have a Buy rating on the stock. Based on 13 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $96.70, reflecting a -35.5% downside.
The insider sentiment on Incyte Corp has been positive according to 81 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.
Read More on INCY:
Incyte (INCY) Shares Remain Attractive, Says Top Analyst
What’s in Store for Incyte Corporation (INCY) After “Big Time” Clinical Miss? Reni Benjamin Chimes In
